Protease-sparing regimen

Protease-sparing regimen is a type of antiretroviral therapy used in the treatment of HIV/AIDS. This regimen does not include protease inhibitors, which are a class of antiviral drugs that prevent viral replication by inhibiting the activity of proteases, enzymes used by the virus to cleave nascent proteins for final assembly of new virions.

Overview

Protease-sparing regimens are used in the management of HIV/AIDS to reduce the risk of drug resistance, improve drug tolerance, and simplify treatment. These regimens typically include two nucleoside reverse transcriptase inhibitors (NRTIs) and a non-nucleoside reverse transcriptase inhibitor (NNRTI) or an integrase inhibitor.

Advantages

The main advantage of protease-sparing regimens is the reduction in the risk of drug resistance. Protease inhibitors are associated with a high rate of resistance, particularly when used as monotherapy. By excluding these drugs from the regimen, the risk of resistance is reduced.

Another advantage is improved drug tolerance. Protease inhibitors are associated with numerous side effects, including lipodystrophy, hyperlipidemia, and insulin resistance. Protease-sparing regimens are generally better tolerated, with fewer side effects.

Disadvantages

The main disadvantage of protease-sparing regimens is that they may be less effective than regimens that include protease inhibitors. This is particularly the case in patients with high viral loads or low CD4 cell counts.

See also

• Antiretroviral therapy
• Protease inhibitor (pharmacology)
• Nucleoside reverse transcriptase inhibitor
• Non-nucleoside reverse transcriptase inhibitor
• Integrase inhibitor